Welcome to our dedicated page for Viemed Healthcare SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viemed Healthcare, Inc. (VMD) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, along with AI-generated summaries to help interpret complex documents. Viemed is incorporated in British Columbia, Canada and files with the SEC under Commission File Number 001-38973, with its common shares listed on NASDAQ under the symbol VMD.
For a company operating as an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, core filings such as the annual report on Form 10-K and quarterly reports on Form 10-Q are central resources. These documents typically contain detailed information on revenue from respiratory equipment and services, operating expenses, cash flows, and risk factors relevant to its non-invasive ventilation, sleep therapy, oxygen therapy, staffing, and related activities.
Viemed also files frequent current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and year-to-date financial results, the completion of a share repurchase program, the acquisition of Lehan’s Medical Equipment, and amendments to the company’s credit agreement that extend certain term loan commitment expiration dates and provide technical changes. Some 8-K filings also furnish investor presentations and financial supplements used in communications with analysts and investors.
On this page, users can review Form 4 and other insider transaction filings, where available, alongside periodic and current reports. Stock Titan’s AI tools summarize lengthy filings, highlight key sections, and surface items such as changes to credit facilities, capital allocation actions, and updates to financial guidance that Viemed has chosen to disclose. Real-time updates from EDGAR ensure that new Viemed filings appear promptly, while AI-generated insights are designed to make the company’s regulatory record more accessible to both experienced and newer investors.
Viemed Healthcare Chief Executive Officer and director Hoyt Casey reported equity compensation-related transactions on common shares dated January 29, 2026. He acquired 39,795 common shares through the vesting and settlement of Restricted Stock Units and 13,265 common shares tied to cash-settled phantom share units.
The company withheld 13,913 common shares at a per-share value of $7.48 to cover Casey’s tax obligations from RSU vesting, and 13,265 common shares were simultaneously disposed of to the company in connection with phantom share settlement. After these transactions, Casey directly owned 350,464 common shares and indirectly held 1,984,943 common shares through Elizabeth Rose Homes LLC.
Viemed Healthcare vice president of sales Jerome Cambre reported equity award vesting and related share movements. On January 29, 2026, 8,619 Restricted Stock Units converted into common shares and 2,873 phantom share units vested into common shares. To cover taxes from RSU vesting, the issuer withheld 2,355 common shares at a per-share value of $7.48, based on the market closing price that day. Following the reported transactions, Cambre directly held 104,088 Viemed common shares.
Viemed Healthcare president Michael Moore reported equity award vesting and related share movements. On January 29, 2026, 26,842 Restricted Stock Units converted into an equal number of common shares, and 8,947 phantom share units vested and were economically settled for common shares before being delivered back to the company for cash.
The issuer withheld 7,342 common shares at $7.48 per share to cover Moore’s tax obligations from the RSU vesting. After these transactions, Moore held 189,090 common shares directly and 1,722,614 common shares indirectly through Moore Faster LLC.
Viemed Healthcare’s General Counsel, Jeremy Trahan, reported equity award vesting and related share movements in company stock. On January 29, 2026, 10,774 restricted stock units converted into the same number of common shares, while 2,939 shares were withheld by the company to cover taxes at a value of $7.48 per share.
The filing also shows 3,591 cash-settled phantom share units vesting, economically equivalent to common shares and settled in cash with matching share movements. After these transactions, Trahan directly holds 46,492 common shares, plus 10,773 restricted stock units and 3,591 phantom share units as continuing equity interests.
Viemed Healthcare, Inc. Chief Medical Officer and director William Frazier reported equity award vesting and related share transactions. On
To cover tax obligations from the RSU vesting, 802 common shares were withheld and disposed of at
Viemed Healthcare Chief Financial Officer Fitzgerald Trae reported equity award activity on January 29, 2026. A block of 9,794 restricted stock units converted into the same number of common shares, and 3,265 cash-settled phantom share units were settled into common shares under the company’s plans.
To cover tax obligations from the restricted stock vesting, 2,679 common shares were withheld by Viemed at a per‑share value of $7.48. In connection with the phantom share settlement, 3,265 common shares were delivered to and simultaneously surrendered back to the company for cash. After these transactions, Trae directly owned 105,638 common shares.
Viemed Healthcare, Inc. Chief Operating Officer and director William Todd Zehnder reported equity compensation vesting and related tax share dispositions. On January 29, 2026, 26,842 restricted stock units converted into an equal number of common shares, and 8,948 cash-settled phantom share units vested, each economically equivalent to one common share.
The company withheld 11,368 common shares at $7.48 per share and a further 8,948 common shares at the same price to cover tax obligations tied to these awards. After these transactions, Zehnder directly owned 390,309 common shares of Viemed Healthcare.
Viemed Healthcare Chief Medical Officer reports equity award vesting and related share transactions. Director and Chief Medical Officer William Frazier reported the vesting of 3,401 Restricted Stock Units (each equal to one common share) and 850 cash-settled phantom share units on January 21, 2026. After these transactions, he directly owned 71,682 common shares.
To cover tax obligations from the RSU vesting, 1,169 common shares were withheld by the company at a per‑share value of $7.49, and 850 common shares were simultaneously acquired and disposed of in connection with settlement of phantom share units for cash. Following the derivative activity, he held 6,800 Restricted Stock Units and 1,700 phantom share units, which were originally granted on January 21, 2025 and vest in three equal annual installments.
Viemed Healthcare President Michael Moore reported equity award vesting and related share movements. On
To cover taxes from RSU vesting, 9,358 common shares were withheld by Viemed Healthcare at a per share value of
Viemed Healthcare, Inc. Chief Executive Officer and director Hoyt Casey reported equity compensation activity and related share movements. On January 21, 2026, 49,597 Restricted Stock Units and 12,400 phantom share units vested, each unit representing the economic equivalent of one common share. In connection with the RSU vesting, the company withheld 13,565 common shares at $7.49 per share to satisfy tax obligations, and 12,400 common shares tied to phantom units were delivered back to the company for cash settlement.
After these transactions, Casey directly holds 324,582 common shares, along with 99,194 RSUs and 24,798 phantom share units. He also has an indirect holding of 1,984,943 common shares through Elizabeth Rose Homes LLC.